World’s First Respiratory Syncytial Virus (RSV) Vaccine Approved by FDABy Tony ZhangJune 7, 20230 The FDA approved Arexvy – the first RSV vaccine for use in the United States in individuals 60 years of age and older. Read more
FDA Approves Omisirge Cell Therapy to Reduce Infection Risk in Patients with Hematologic MalignanciesBy kethleen lohJune 6, 20230 Omisirge is used in adults and children aged 12+ for cord blood transplant after myeloablative conditioning in hematologic malignancies.
Case Study: Filipino on Doxorubicin and Cyclophosphamide Experienced Disturbed ConsciousnessBy Kit YarnJune 2, 20230 Doxorubicin and Cyclophosphamide is a commonly used combination but their use has rarely led to diagnosis of type 1 diabetes.
Dexamethasone for Hospitalized COVID-19 Patients – A New National Cohort StudyBy Tony ZhangMay 31, 20230 Many geriatricians have branded dexamethasone as the ‘golden bullet’ in treating systemic discomfort in elderly populations. Read more
NSAID Use Increased First Heart Failure Hospitalization Risk In Those With Type 2 Diabetes MellitusBy kethleen lohMay 24, 20230 A study in Denmark found that short-term use of NSAIDs increases heart failure hospitalization risk in type 2 diabetes patients. Read more
Cases of Notable Medical Malpractice and Lawsuits in AsiaBy Tony ZhangMay 19, 20230 This article will bring you some of the headline-making medical malpractices and/or lawsuits in Asia. Read more
Case Study: 43-year-old Asian Female with Postural Dizziness and Hypertension after Diclofenac Sodium SRBy Kit YarnMay 17, 20230 Prompt recognition and early treatment with adrenaline are important in the treatment of suspected anaphylaxis.
Burnout Rates of Medical Workers in Southeast Asia & Reasons Behind ThemBy Tony ZhangMay 17, 20230 Despite seeing these reports of healthcare burnout on the news, how bad is the situation? How common is it in medical workers?
Bluebird Bio’s Lovo-Cel For Sickle Cell Disease Finally Under FDA ReviewBy Tony ZhangMay 12, 20230 Bluebird Bio1 submits application to FDA for gene therapy lovo-cel for approval to treat people aged 12+ with sickle cell disease
The FDA has Granted Full Approval to Pembrolizumab for the Treatment of Unresectable Or Msi-H Or Dmmr Solid TumourBy Tony ZhangMay 8, 20230 This marks the first-ever FDA approval for immunotherapy based on a predictive biomarker, regardless of solid tumour type.
